88326
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 2
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -4.812002621
- umap2_2d
- 0.374614602
- umap1_3d
- 0.804614143
- umap2_3d
- 3.615692506
- umap3_3d
- -0.511000662
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- IL6_JAK_STAT3_SIGNALING+0.320
- ADIPOGENESIS+0.300
- FATTY_ACID_METABOLISM+0.300
- IL2_STAT5_SIGNALING+0.300
- OXIDATIVE_PHOSPHORYLATION+0.290
- PEROXISOME+0.290
- BILE_ACID_METABOLISM+0.280
Top 10 suppressed
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.470
- MYC_TARGETS_V1-0.270
- MYC_TARGETS_V2-0.230
- MITOTIC_SPINDLE-0.220
- PANCREAS_BETA_CELLS-0.220
- ANDROGEN_RESPONSE-0.210
- WNT_BETA_CATENIN_SIGNALING-0.170
- SPERMATOGENESIS-0.120
- MTORC1_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 131532 | EPN | EPN Tumor | 0.840 |
| 2 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.822 |
| 3 | SRR10900573 | — | — | 0.819 |
| 4 | BS_YCREDZTJ | low-grade glioma | — | 0.814 |
| 5 | BS_WG203ECV | pilocytic astrocytoma | — | 0.810 |
| 6 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.805 |
| 7 | BS_XQ5SFW35 | high-grade glioma | — | 0.805 |
| 8 | BS_3G3KWY18 | low-grade glioma | — | 0.803 |
| 9 | BS_NB5XWMJT | low-grade glioma | — | 0.799 |
| 10 | BS_JVA2NQFF | pilocytic astrocytoma | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |